ACELRX PHARMACEUT. DL-01
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulat… Read more
ACELRX PHARMACEUT. DL-01 (R5XA) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ACELRX PHARMACEUT. DL-01 (R5XA) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ACELRX PHARMACEUT. DL-01 - Net Assets Trend (None–None)
This chart illustrates how ACELRX PHARMACEUT. DL-01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ACELRX PHARMACEUT. DL-01 (None–None)
The table below shows the annual net assets of ACELRX PHARMACEUT. DL-01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ACELRX PHARMACEUT. DL-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ACELRX PHARMACEUT. DL-01 Competitors by Market Cap
The table below lists competitors of ACELRX PHARMACEUT. DL-01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sunshine Oilsands Ltd
PINK:SUNYF
|
$17.61 Million |
|
Ai-Media Technologies Ltd
AU:AIM
|
$17.62 Million |
|
VAA Vista Alegre Atlantis SGPS SA
LS:VAF
|
$17.62 Million |
|
Glidelogic Corp.
PINK:GDLG
|
$17.64 Million |
|
Chilwa Minerals Ltd
AU:CHW
|
$17.61 Million |
|
African Rainbow Minerals Ltd
JSE:ARI
|
$17.61 Million |
|
Fulin Plastic Industry Cayman Holding Co Ltd
TW:1341
|
$17.61 Million |
|
N R Agarwal Industries Limited
NSE:NRAIL
|
$17.60 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ACELRX PHARMACEUT. DL-01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ACELRX PHARMACEUT. DL-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ACELRX PHARMACEUT. DL-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ACELRX PHARMACEUT. DL-01's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ACELRX PHARMACEUT. DL-01 (R5XA) | €- | N/A | N/A | $17.61 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |